The kit has since been used in clinical trials involving 2,347 patients at eight hospitals in China. It was the first clinical trial in the world to test if the protein could be a useful tumor biomarker for lung cancer, and it succeeded.

该试剂盒此后被应用于临床试验，已对国内8家医院的2347例患者进行测试。这是世界上首个研究热休克蛋白90α能否作为肺癌的有效肿瘤生物标志物的临床试验，也是首个成功的试验。

Now, the kit has been certified to enter the Chinese and European markets, 24 years after Hsp90α was discovered.

在发现热休克蛋白90α24年后，该试剂盒现已经获准进入中国和欧盟市场。

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

癌症是异常细胞生长且可能侵入或扩散至身体其他部位的一系列疾病。

In 2017, about 90.5 million people had cancer in the world, with roughly 14.1 million new cases occurring each year. Approximately 8.8 million human deaths, or 15.7 percent of all deaths in the world, are caused by cancer.

2017年，全球约有9050万例癌症患者，每年大约有1410万例新生病例。约有880万人死于癌症，占全球死亡人数的15.7%。

In China alone, 4.29 million people were detected as having cancer in 2017, and 2.8 million of them died in that year.

【重大突破！一滴血可测癌症，已被批准临床使用】相关文章：

★ 苹果的优势在于软件

★ 伦敦英国白人不再占多数

★ 巴西利亚：过度城市规划的警示

★ 民众提前45小时排队买奥运门票

★ 奥运让北京更文明

★ 三星要求复审与苹果专利权纠纷

★ FT社评：欧元区应迅速化解希腊援助僵局

★ 印度巴士轮奸案嫌犯被起诉

★ 华为计划在诺基亚后院扩张业务

★ 中概股在美受挫 美国交易所被批看门不力